Perrigo Company plc (PRGO)
PRGO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1585364/000158536426000009/0001585364-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRGO on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001585364 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Ireland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.3B |
| Net income | -$1.4B |
| Operating income | -$1.1B |
| Net margin | -33.5% |
| Operating margin | -26.4% |
| Revenue growth | -2.8% |
| Cash | $531.6M |
| Total assets | $8.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $436.6M cash; operating cash flow $60.1M a quarter. | Report 2026-09-26 |
| Shares outstanding | 138,801,872 (2026-10-30); 137,624,009 a year earlier; 135,506,489 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2024-12-16 |
| Auditor | Ernst & Young LLP, Grand Rapids, Michigan, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $106K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-26 | $988.6M | -$27.5M | $96.2M | $436.6M | $3.3B | $4.1B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-27 | $1.0B | $74.5M | $82.6M | $399.7M | $3.3B | $4.1B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-28 | $969.2M | -$398.6M | -$113.6M | $357.2M | $3.6B | $4.2B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $1.1B | -$1.4B | $175.4M | $531.6M | $3.6B | $4.3B | 10-K 2026-02-26 |
| Q3 2025 2025-09-27 | $1.0B | $7.5M | $51.7M | $432.1M | $3.6B | $4.3B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-28 | $1.1B | -$8.4M | $75.9M | $454.2M | $3.7B | $4.3B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-29 | $1.0B | -$6.4M | -$64.5M | $409.9M | $3.6B | $4.3B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $1.1B | -$44.5M | $312.6M | $558.8M | $3.6B | $4.4B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-09-13 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-03 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.5% |
| 1 month | +5.7% |
| 3 months | +26.6% |
| Year to date | +16.7% |
| 1 year | +16.2% |
| From 52-week high | -4.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PHVS | Pharvaris N.V. | $32.44 | -2.76% | $2.3B |
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
| LKFT | Lakefront Biotherapeutics | $34.79 | +2.38% | $2.3B |
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier